The present invention relates to alanine N-acetic acid precursors of formula (i) COOM-CH(CH3)NH(CH2CN), wherein M is hydrogen (alanine N-monoacetonitrile), or (ii) COOM-CH(CH3)N(CH2CN)2, wherein 0 to 50% of all M is sodium or potassium and 50 to 100% of all M is hydrogen (alanine N,N-diacetonitrile and its partial sodium or potassium salts) comprising L-alanine to D-alanine in a range of from 75:25 to 50:50 (L:D), or (iii) COOM-CH(CH3)N(CH2CONH2)2, wherein M is hydrogen (alanine N,N-diacetamide), in the form of crystals, and relates to a process to prepare these precursors and their use, especially to give MGMA or MGDA.

The present invention relates to alanine N-acetic acid precursors of formula (i) COOM-CH(CH3)NH(CH2CN), wherein M is hydrogen (alanine N-monoacetonitrile), or (ii) COOM-CH(CH3)N(CH2CN)2, wherein 0 to 50% of all M is sodium or potassium and 50 to 100% of all M is hydrogen (alanine N,N-diacetonitrile and its partial sodium or potassium salts) comprising L-alanine to D-alanine in a range of from 75:25 to 50:50 (L:D), or (iii) COOM-CH(CH3)N(CH2CONH2)2, wherein M is hydrogen (alanine N,N-diacetamide), in the form of crystals, and relates to a process to prepare these precursors and their use, especially to give MGMA or MGDA.

The present invention provides a process for the preparation of crystalline anhydrous compound of Formula (X), Further, the present invention relates to the use of compound of Formula (X) preparation of Raltegravir (I) or its pharmaceutically acceptable salt thereof. ##STR00001##

The present invention provides a process for the preparation of crystalline anhydrous compound of Formula (X), Further, the present invention relates to the use of compound of Formula (X) preparation of Raltegravir (I) or its pharmaceutically acceptable salt thereof. ##STR00001##

The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.

The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.

The present invention relates to a compound of formula (I):

##STR00001##

in which: the R.sub.1 and R.sub.2 groups, which may be identical or different, are, independently of one another, a saturated or unsaturated, linear, branched or cyclic hydrocarbon group having from 1 to 15 carbon atoms, preferably from 1 to 10 carbon atoms; the R.sub.3 and R.sub.4 groups, which may be identical or different, are selected, independently of one another, from a hydrogen atom, a methyl group or an ethyl group; the R, R.sub.6 and R.sub.7 groups, which may be identical or different, are selected, independently of one another, from a hydrogen atom or an alkyl group comprising from 1 to 6 carbon atoms; n is an integer of 0 to 20; and m is an integer of 1 to 6.

Process for preparation of a mixture of methyl glycine diacetic acid (MGDA) or its respective mono-, di-, trialkali metal salt or its respective mono-, di- or tri-ammonium salt or mixtures thereof, and glutamic acid diacetic acid (GLDA) or its respective mono-, di-, tri-, or tetra-alkali metal or mono-, di-, tri- or tetra-ammonium salt or mixtures thereof, wherein said process com-prises the steps of: (a) dissolution in water of (a1) alanine in its L- or D-enantiomeric form or its respective monoalkali metal salt or mixtures thereof, and (a2) glutamic acid as L- or D-enantiomer or its respective mono-, or dialkali metal or mixtures thereof, wherein the molar ratio of alanine to glutamic acid is in the range of from 1:9 to 9:1, (b) converting the mixture obtained in step (a) with formaldehyde and hydrocyanic acid or alkali metal cyanide to the corresponding dinitriles, (c) saponification of the dinitriles resulting from step (b).

Process for preparation of a mixture of methyl glycine diacetic acid (MGDA) or its respective mono-, di-, trialkali metal salt or its respective mono-, di- or tri-ammonium salt or mixtures thereof, and glutamic acid diacetic acid (GLDA) or its respective mono-, di-, tri-, or tetra-alkali metal or mono-, di-, tri- or tetra-ammonium salt or mixtures thereof, wherein said process com-prises the steps of: (a) dissolution in water of (a1) alanine in its L- or D-enantiomeric form or its respective monoalkali metal salt or mixtures thereof, and (a2) glutamic acid as L- or D-enantiomer or its respective mono-, or dialkali metal or mixtures thereof, wherein the molar ratio of alanine to glutamic acid is in the range of from 1:9 to 9:1, (b) converting the mixture obtained in step (a) with formaldehyde and hydrocyanic acid or alkali metal cyanide to the corresponding dinitriles, (c) saponification of the dinitriles resulting from step (b).

The present invention relates to a non-aqueous electrolyte additive, and a non-aqueous electrolyte for a lithium secondary battery including the same and a lithium secondary battery, and particularly, to a non-aqueous electrolyte additive having a nitrile group and a propargyl group, and a non-aqueous electrolyte for a lithium secondary battery and a lithium secondary battery, which include the non-aqueous electrolyte additive so that capacity and cycle lifespan characteristics at high temperature can be improved.